Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation

Molecular and Cellular Biology

Volumn 17, Issue 1, 1997, Pages 355-363

  Maki, Carl G ^a   Howley, Peter M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PROTEIN P53; UBIQUITIN;

ARTICLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DNA DAMAGE; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE MUTATION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN STABILITY; RADIATION EXPOSURE; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

EID: 0031015044     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.1.355     Document Type: Article

References (58)

1. Abrahamson, J. L., J. M. Lee, and A. Bernstein. 1995. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. Mol Cell. Biol. 15:6953-6960.
2. Bae, I., S. Fan, K. Bhatia, K. W. Kohn, A. J. Fornace, Jr., and P. M. O'Connor. 1995. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells. Cancer Res. 55:2387-2393.
3. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.
4. Canman, C. E., A. C. Wolff, C. Y. Chen, A. J. Fornace, Jr., and M. B. Kastan. 1994. The p53-dependent G1 cell cycle checkpoint pathway and ataxiatelangiectasia. Cancer Res. 54:5054-5058.
5. Ciechanover, A. 1994. The ubiquitin-proteasome proteolytic pathway. Cell 79:13-22.
6. Cox, L. S., and D. P. Lane. 1995. Tumor suppressors, kinases, and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays 17:501-508.
7. Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind, and B. J. Reid. 1995. A p53-dependent mouse spindle checkpoint. Science 267:1353-1356.
8. Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21Cip1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.
9. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356: 215-221.
10. Donehower, L. A., L. A. Godley, C. M. Aldaz, R. Pyle, Y. P. Shi, D. Pinkel, J. Gray, A. Bradley, D. Medina, and H. E. Varmus. 1995. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 9:882-895.
11. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
12. Eyfjord, J. E., S. Thorlacius, and M. Steinarsdottir. 1995. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res. 55:646-651.
13. Fenteany, G., R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino terminal threonine modification by lactacystin. Science 268:726-731.
14. Florenes, V. A., G. M. Maelandsmo, A. Andreassen, O. Myklebost, and O. Fodstad. 1994. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J. Natl. Cancer Inst. 86:1297-1302.
15. Glotzer, M., A. W. Murray, and M. W. Kirschner. 1991. Cyclin is degraded by the ubiquitin pathway. Nature 349:132-138.
16. Guarino, L. A., G. Smith, and W. Dong. 1995. Ubiquitin is attached to membranes of baculovirus particles by a novel type of phospholipid anchor. Cell 80:301-309.
17. Han, J., P. Sabbatini, D. Perez, L. Rao, D. Modha, and E. White. 1996. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death promoting Bax protein. Genes Dev. 10:461-477.
18. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
19. Havre, P. A., J. Yuan, L. Hedrick, K. R. Cho, and P. M. Glazer. 1995. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 55:4420-4424.
20. Hershko, A., and A. Ciechanover. 1992. The ubiquitin system for protein degradation. Annu. Rev. Biochem. 61:761-807.
21. Hochstrasser, M. 1995. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr. Opin. Cell Biol. 7:215-223.
22. Hollstein, M., B. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
23. Huibregtse, J. M., M. Scheffner, and P. M. Howley. 1991. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus type 16 or 18. EMBO J. 10:4129-4135.
24. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg. 1994. Tumour spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.
25. Kaneko, Y., and A. Tsukamoto. 1995. Apoptosis and nuclear levels of p53 protein and proliferating cell nuclear antigen in human hepatoma cells cultured with tumor promoters. Cancer Lett. 91:11-17.
26. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
27. Kastan, M. B., Q. Zhan, W. S. el-Diery, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597.
28. Kessis, T. D., R. J. Slebos, W. G. Nelson, M. B. Kastan, B. S. Plunkett, S. M. Han, A. T. Lorincz, L. Hedrick, and K. R. Cho. 1993. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90:3988-3992.
29. Khanna, K. K., and M. F. Lavin. 1993. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8:3307-3312.
30. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
31. Labrecque, S., and G. J. Matlashewski. 1995. Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: the use of human papillomavirus E6 to target p53. Oncogene 11:387-392.
32. Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849.
33. Lu, X., S. A. Burbridge, S. Griffin, and H. M. Smith. 1996. Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation. Oncogene 13:413-418.
34. Lu, X., and D. P. Lane. 1993. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75:765-778.
35. 34a.Maki, C. G., and P. M. Howley. Unpublished results.
36. Maki, C. G., J. M. Huibregtse, and P. M. Howley. 1996. In vivo ubiquitination and proteasome mediated degradation of p53. Cancer Res. 56:2649-2654.
37. Maltman, W., and L. Czyzyk. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1689-1694.
38. Meyn, M. S. 1995. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res. 55:5991-6001.
39. Meyn, M. S., L. Strasfeld, and C. Allen. 1994. Testing the role of p53 in the expression of genetic instability and apoptosis in ataxia-telangiectasia. Int. J. Radiat. Biol. 66(Suppl.):141-149.
40. Milne, D. M., L. E. Campbell, D. G. Campbell, and D. W. Meek. 1995. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase JNK1. J. Biol. Chem. 270: 5511-5518.
41. Mirzayans, R., K. S. Famulski, L. Enns, M. Fraser, and M. C. Patterson. 1995. Characterization of the signal transduction pathway mediating gamma ray-induced inhibition of DNA synthesis in human cells: indirect evidence for involvement of calmodulin but not protein kinase C nor p53. Oncogene 11:1597-1605.
42. Mosner, J., T. Mummenbrauer, C. Bauer, G. Sczakiel, F. Grosse, and W. Deppert. 1995. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 14:4442-4449.
43. Nabeya, Y., F. Loganzo, Jr., P. Maslak, L. Lai, A. R. de Oliveira, G. K. Schwartz, M. L. Blundell, N. K. Altorki, D. P. Kelsen, and A. P. Albino. 1995. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int. J. Cancer 64:37-46.
44. Pagano, M., S. W. Tam, A. M. Theodoras, P. Beer-Romano, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta, and M. Rolfe. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
45. Perego, P., M. Giarola, S. C. Righetti, R. Supino, C. Caserini, D. Delia, M. A. Pierotti, T. Miyashita, J. C. Reed, and F. Zunino. 1996. Association between cisplatin resistance and mutation of p53 gene and reduced hax expression in ovarian carcinoma cell systems. Cancer Res. 56:556-562.
46. Perry, M. E., J. Piette, J. A. Zawadzki, D. Harvey, and A. J. Levine. 1993. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA 90:11623-11627.
47. Price, B. D., and M. B. Youmell. 1996. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 56:246-250.
48. Rock, K. L., A. L. Goldberg, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-772.
49. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
50. Scheffner, M., J. M. Huibregtse, R. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
51. Scheffner, M., U. Nuber, and J. M. Huibregtse. 1995. Protein ubiquitination involving an E1-E2-E3 ubiquitin thioester cascade. Nature 373:81-83.
52. Schwob, E., T. Bohm, M. D. Mendenhall, and K. Nasmyth. 1994. The B-type cyclin kinase inhibitor p40 controls the G1 to S transition in S. cerevisiae. Cell 79:233-244.
53. Smith, M. L., and A. J. Fornace. 1995. Genomic instability and the role of p53 mutations in cancer cells. Curr. Opin. Oncol. 7:69-75.
54. Smith, M. L., I. T. Chen, Q. Zhan, P. M. O'Connor, and A. J. Fornace, Jr. 1995. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10:1053-1059.
55. Trier, M., L. M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain. Cell 78:787-798.
56. Tsang, N.-M., H. Nagasawa, C. Li, and J. B. Little. 1995. Abrogation of p53 function by transfection of HPV16E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 10:2403-2408.
57. Whitacre, C. M., H. Hashimoto, M. L. Tsai, S. Chatterjee, S. J. Berger, and N. A. Berger. 1995. Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res. 55:3697-3701.
58. Xiong, Y., G. J. Hannon, H. Zhang, D. Casco, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.